Adma Biologics (ADMA) Interest Expenses (2011 - 2025)

Adma Biologics has reported Interest Expenses for 13 years, with the latest figure at $1.6 million in Q4 2025.

• For the quarter ending Q4 2025, Interest Expenses fell 43.52% year-over-year to $1.6 million; the trailing twelve-month figure through Dec 2025 stood at $7.1 million (down 48.96% YoY), and the FY2025 full-year result was $7.1 million, down 48.96% from the prior year.
• Interest Expenses for Q4 2025 stood at $1.6 million, down from $1.7 million in the prior quarter.
• The five-year high for Interest Expenses was $6.4 million in Q3 2023, with the low at $1.6 million in Q4 2025.
• Historically, Interest Expenses has averaged $3.9 million across 5 years, with a median of $3.4 million in 2022.
• Annual changes were most pronounced in 2021 — Interest Expenses surged 50860.29% — and 2024, when it sank 53.68%.
• Adma Biologics' Interest Expenses stood at $3.3 million in 2021, then jumped by 73.0% to $5.7 million in 2022, then advanced by 8.34% to $6.2 million in 2023, then slumped by 53.68% to $2.9 million in 2024, then sank by 43.52% to $1.6 million in 2025.
• The last three Interest Expenses figures came in at $1.6 million (Q4 2025), $1.7 million (Q3 2025), and $1.8 million (Q2 2025), per Business Quant data.